ZGN-440 for Injectable Suspension

DRUG3 trials

Sponsors

Zafgen, Inc.

Conditions

CraniopharyngiomaHypothalamic InjuryObesityOver-weightPrader-Willi SyndromeType 2 Diabetes

Phase 2

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

CompletedNCT02063295

Zafgen, Inc.Craniopharyngioma, Hypothalamic Injury, Obesity +1

Start: 2014-04-30End: 2014-11-30Updated: 2016-07-18

An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

TerminatedNCT02324491

Zafgen, Inc.Obesity, Type 2 Diabetes

Start: 2014-12-31End: 2015-12-31Updated: 2016-01-06

Phase 3

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

TerminatedNCT02179151

Zafgen, Inc.Obesity, Prader-Willi Syndrome

Start: 2014-09-30End: 2016-10-31Updated: 2017-01-26

Related Papers

Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.

2018-07-1114 citations

Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.

2017-07-1378 citations